Stephen A. Carter, Informa Group Chief Executive, said: “The addition of Dove Medical Press adds strength and capability to our OA portfolio, further increasing choice and flexibility for researchers across a widening range of subject areas.”
He added: “Its track record, publishing platform and growing reputation in Health Sciences enhance our Journals business, strengthening our position in the attractive and growing OA market.”
Dove Medical Press is an independent OA journals publisher, founded in 2003, producing a range of OA journals, mainly in Health Sciences, with additional content in Science and Technology. A large proportion of its journals are indexed by the Web of Science and PubMed and a growing number have established and improving impact factors, says Informa. Leading titles include OncoTargets and Therapy, International Journal of Nanomedicine and Clinical Ophthalmology.
The addition of Dove Medical Press complements the growing portfolio of OA titles published under the Taylor & Francis and Cogent brands, enabling continued expansion in the attractive OA market, says the company. Following the acquisition, Informa will publish more than 200 OA journals, as part of a total journal portfolio of more than 2,500 titles.
Financial details were not disclosed but Informa expects the transaction to be modestly accretive to adjusted earnings in the first full year of ownership and deliver a return on investment ahead of the cost of capital within three years.
